Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New shareholder

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 18, 2024 8:53pm

112 Views

Post# 35997160

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New shareholder

Well while you may not see the "math", as you described, others do and I've already described ONCY's or acquirer's path to an Accelerated Approval. I am not prepared to rehash old debates with you or anyone else, so I suggest that you do quite a bit more due diligence rather than describing your fears" as a newcomer. If you were so fearful, what ate you doing here now?, especially since you have nothing to offer, as has become evidently clear .

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?